Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.49 |
| ▸ | RARG | P13631 | 3/20 | 0.49 |
| ▸ | RARB | P10826 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612956 | 0.91 | MAOB (0.49) | RARARARGRARBPTGS2NR1H4 | |
| SCHEMBL952469 | 0.83 | NR1H4 (0.54) | RARARARGRARBPTGS2NR1H4 | |
| Idronoxil SCHEMBL149612 | 0.81 | ESR2 (0.49) | RARARARGRARBNR1H4TYR | |
| Idronoxil SCHEMBL29353213 | 0.81 | ESR2 (0.49) | RARARARGRARBNR1H4TYR | |
| SCHEMBL4291569 | 0.80 | KMT2A (0.53) | RARARARGRARBPTGS2NR1H4 | |
| SCHEMBL614571 | 0.80 | NR1H4 (0.51) | RARARARGRARBNR1H4TYR | |
| SCHEMBL676933 | 0.79 | TYR (0.45) | RARARARGRARBNR1H4TYR | |
| SCHEMBL614015 | 0.78 | PTGS2 (0.44) | RARARARGRARBPTGS2NR1H4 | |
| SCHEMBL30628176 | 0.78 | TYR (0.47) | RARARARGRARBPTGS2NR1H4 | |
| SCHEMBL2072026 | 0.77 | KMT2A (0.49) | RARARARGRARBPTGS2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367659-B2 | Oxazinyl isoflavonoid compounds, medicaments and use | MARSHALL EDWARDS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2125831-B1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RES PTY LTD (AU) | 2011-12-28 | — | — | EP | disclosed |
| EP-2334296-A1 | IMMUNOMODULATING ACTIVITIES | Novogen Research Pty. Ltd. (AU) | 2011-06-22 | — | — | EP | disclosed |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2011-02-24 | — | — | US | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| EP-2125831-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | Novogen Research Pty. Ltd. (AU) | 2009-12-02 | — | — | EP | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| WO-2008106715-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | RARA 743/4885RARG 312/4885RARB 818/4885 |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | TNNI3, NFE2L2, OAT | RARA 4617/4885RARG 4274/4885RARB 4581/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | RARA 2668/4885RARG 1604/4885RARB 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.